Development of new vaccines or biologics is a lengthy and costly endeavor which often fails due to lack of therapeutic effect or due to safety concern. A key challenge for drug developers is getting a lead drug candidate with the right immune-stimulating properties in human. Immunitrack’s mission is to provide the research community with tools to select or redesign drug candidates at the early stage of R&D but also to provide reagents to monitor lead drug candidates effect on patient’s immune system.

The biotinylated MHC molecules from Immunitrack have proven their performance as assay reagents in several large scale NIH funded projects, as a way of example approximately 100.000 affinity measurements in the Immune Epitope Database (EIDB) are based on these protocols. Additionally our biotinylated MHC II molecules have served as superior tetramer reagents in several peer reviewed articles. The combination of our assay technology and supporting MHC I/II molecules for staining or expansion of CD4/8 T cells makes us the ideal partner in any immunogenicity, vaccine or immunotherapy project.

Immunitrack supply FcRn molecules from a variety of species, the molecules can be enzymatically biotinylated at the C terminus of the FcRn heavy chain enabling IgG and albumin to bind at the same time. The molecules are captured on IgG sepharose and therefore 100 percent active, the molecules have been tested and show superior performance on a variety of assay platforms: ELISA, AlphaScreen, BLI (Octet) and SPR (Biacore).